Galvus Safety Trial Reconsidered In Light Of Novartis Cost Concerns
Executive Summary
Novartis' NDA for its oral type 2 diabetes drug Galvus (vildagliptin) will remain in a holding pattern in the U.S. until the firm has a clearer idea of whether it can gain FDA approval without excessive expenditures to gather additional safety data
You may also be interested in...
Boehringer Ingelheim Plays Catch-Up In Diabetes, Close To Filing DPP-4 Drug
As part of its ongoing effort to develop drugs for metabolic disease, Boehringer Ingelheim is gearing up for a filing within the next few months of its first diabetes drug - the DPP-4 inhibitor linagliptin
Boehringer Ingelheim Plays Catch-Up In Diabetes, Close To Filing DPP-4 Drug
As part of its ongoing effort to develop drugs for metabolic disease, Boehringer Ingelheim is gearing up for a filing within the next few months of its first diabetes drug - the DPP-4 inhibitor linagliptin
Bristol Myers-Squibb/AstraZeneca's Onglyza Officially Cleared For Europe
New DPP-4 inhibitor for diabetes passes noninferiority test against Merck's hugely popular Januvia.